

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7577525

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
BRADFORD C. SIPPY	01/14/2020
RAYMOND D. SKWIERCZYNSKI	01/14/2020
JEAN-MARIE SCHNEIDER	01/09/2020
SIMON H. DROUIN	01/09/2020
CHARLES GUERIN	01/09/2020
RECEIVING PARTY DATA	
Name:	TREMEAU PHARMACEUTICALS, INC.
Street Address:	53 MAIN STREET
Internal Address:	SUITE 202
City:	CONCORD
State/Country:	MASSACHUSETTS
Postal Code:	01742
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17856549
CORRESPONDENCE DATA	
Fax Number:	(617)646-8646
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6176468000
Email:	Katherine.Mills@WolfGreenfield.com, Jonathan.Roses@wolfgreenfield.com
Correspondent Name:	JONATHAN B. ROSES
Address Line 1:	WOLF, GREENFIELD & SACKS P.C.
Address Line 2:	600 ATLANTIC AVENUE
Address Line 4:	BOSTON, MASSACHUSETTS 02210-2211
ATTORNEY DOCKET NUMBER:	T0848.70001US05
NAME OF SUBMITTER:	JONATHAN B. ROSES
SIGNATURE:	/Jonathan Ben-Ur Roses/
DATE SIGNED:	10/06/2022

Total Attachments: 8

source=T084870001US05-ASI-JBR#page1.tif

source=T084870001US05-ASI-JBR#page2.tif

source=T084870001US05-ASI-JBR#page3.tif

source=T084870001US05-ASI-JBR#page4.tif

source=T084870001US05-ASI-JBR#page5.tif

source=T084870001US05-ASI-JBR#page6.tif

source=T084870001US05-ASI-JBR#page7.tif

source=T084870001US05-ASI-JBR#page8.tif

ASSIGNMENT

WHEREAS, the undersigned, to wit:

- Bradford C. SIPPY residing at 200 Newtown Road, Acton, Massachusetts 01720, UNITED STATES OF AMERICA;
- Raymond D. SKWIERCZYNSKI, Ph.D. residing at 122 Salem Street, Andover, Massachusetts 01810, UNITED STATES OF AMERICA;
- Jean-Marie SCHNEIDER residing at 11, Chemin des Merles, 78 200 Magnaville, FRANCE;
- Simon H. DROUIN residing at 2275 av Pagé, Saint-Hyacinthe, Quebec J2S 4C8, CANADA;
- Charles GUERIN, Ph.D. residing at 6 Boulevard Roger Salengro, 78711 Mantes La Ville, FRANCE

(hereinafter collectively “ASSIGNORS”), have made a certain new and useful invention as set forth in an application for United States Letters Patent, entitled:

“PURIFIED FORMS OF ROFECOXIB, METHODS OF MANUFACTURE AND USE”

- (a) which is being filed herewith in the United States Patent and Trademark Office;
- (b) which was filed as International Patent Application No. PCT/US19/61178
on November 13, 2019 ;
- (c) which was filed as International Patent Application No. _____
on _____ designating the United States; and

WHEREAS, Tremeau Pharmaceuticals, Inc. (hereinafter “ASSIGNEE”), a corporation organized and existing under the laws of the State of Delaware, and having its principal place of business at 53 Main Street, Suite 202, Concord, Massachusetts 01742, is desirous of acquiring the entire right, title, and interest in and to said invention and any and all patents that may be obtained therefor, and in and to said application and any and all patents that may issue therefrom;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, ASSIGNORS do hereby sell, assign, transfer, and set over unto said ASSIGNEE, its successors, assigns, and legal representatives, all right, title, and interest in and to said invention throughout the world, and any and all patents of the United States and foreign countries that may be obtained therefor, including the right to sue for past

infringement and obtain past damages, and in and to said application, including any and all non-provisionals, continuations, continuations-in-part, divisionals, reissues, re-examinations, substitutions, and extensions thereof, and any and all patents of the United States and foreign countries that may issue therefrom, such right, title, and interest including the right to file applications and obtain patents, utility models, industrial models, and designs for said invention in the name of said ASSIGNEE, its successors, assigns, and legal representatives, throughout the world, including all rights of priority, all rights to publish cautionary notices reserving ownership of said invention, and all rights to register said invention in appropriate registries;

ASSIGNORS also do hereby covenant that they have the full right to convey the entire right, title, and interest herein assigned, and that they have not and will not execute any agreement in conflict herewith;

ASSIGNORS also do hereby authorize and request the Commissioner of Patents and Trademarks to issue any and all Letters Patent of the United States on said invention or resulting from said application, including any continuations, continuations-in-part, divisionals, reissues, re-examinations, substitutions, and extensions thereof, to said ASSIGNEE, its successors, assigns, and legal representatives as the ASSIGNEE of the entire right, title, and interest herein assigned;

ASSIGNORS also do hereby agree to, at any time, upon request, without further or additional consideration but at the expense of said ASSIGNEE, its successors, assigns, or legal representatives, execute and deliver any and all papers, make all rightful oaths, and do all lawful acts that may be necessary or desirable to perfect the entire right, title, and interest in said application, including any and all continuations, continuations-in-part, divisionals, reissues, re-examinations, substitutions, and extensions thereof, and any and all patents of the United States and foreign countries that may issue therefrom to said ASSIGNEE, its successors, assigns, and legal representatives, and generally do everything possible to vest the entire right, title, and interest herein assigned in said ASSIGNEE, its successors, assigns, and legal representatives;


ASSIGNORS also do hereby grant to ASSIGNEE, its successors and assigns, and legal representatives thereof, including the following individuals, the power to insert on this Assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office or foreign equivalent thereof for recordation of this document:

WILMER CUTLER PICKERING HALE AND DORR LLP


All practitioners at Customer Number 23483

This ASSIGNMENT is effective as of November 13, 2019 .

14-Jan-2020
Date


Bradford C. Sippy

Witness:
14 Jan 2020
Date



14 Jan 2020

Date



Raymond D. Skwierzynski, Ph.D.

Witness:


14-Jan-2020

Date




Brad Sippy

January 09, 2020
Date



Jean-Marie Schneider

Witness:

January 09, 2020
Date




January 9, 2020
Date


Simon H. Drouin


Witness:

January 9, 2020
Date


FRANCOIS A. AMADIO

January, 9th 2020

Date




Charles Guerin, Ph.D.

Witness:

January, 9th 2020

Date



Adeline AGOT

ASSIGNEE hereby acknowledges and accepts the foregoing assignment.

Tremeau Pharmaceuticals, Inc.

Signature:



Date:

15-Jan-2020

Name:

Brad Sippy

Title:

CEO